Could a daily pill shield transplant patients from a common virus?

NCT ID NCT07706166

Not yet recruiting Prevention Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study investigates whether the drug letermovir can prevent cytomegalovirus (CMV) infection in adults who have received a kidney or liver transplant and have been previously exposed to CMV. Participants take one letermovir tablet daily for 84 days after transplant. The goal is to see if this approach reduces the rate of CMV breakthrough or treatment withdrawal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: letermovir
What this could lead to: If effective, letermovir could become a standard preventive treatment for CMV in moderate-risk transplant recipients, reducing infection-related complications.
What could go wrong: This is a single-arm Phase 4 study with no placebo comparison, so results may be less definitive. The drug may cause side effects or fail to prevent CMV in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT LIVER TRANSPLANT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Wisconsin - Madison

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.